November 4th 2024
An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
February 29th 2024Immune engager therapies, according to a retrospective study of real-world patients, had the best rates of responses and progression-free survival in patients with multiple myeloma whose disease relapsed after treatment with idecabtagene vicleucel.
Bi-weekly Teclistamab Dosing Receives FDA Approval for Relapsed/Refractory Multiple Myeloma
February 21st 2024A supplemental Biologics License Application for teclistamab-cqyv (Tecvayli) has been approved by the FDA at a reduced dose of 1.5 mg/kg every 2 weeks for the treatment of patients with relapsed/refractory multiple myeloma who have maintained a complete response or greater for at least 6 months.
Belantamab Mafodotin Plus Vd Significantly Improves PFS in Relapsed/Refractory Multiple Myeloma
February 9th 2024Patients with relapsed/refractory multiple myeloma treated with belantamab mafodotin plus bortezomib and dexamethasone experienced a significant improvement in PFS compared with daratumumab plus bortezomib and dexamethasone.
Nurses Compare Tactics in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
December 18th 2023During a Case-Based Roundtable™ event, Beth Faiman, Phd, CNP, and participants discussed the use of combination therapies, including daratumumab, as frontline therapy for patients with transplant-ineligible multiple myeloma.
FDA Approves Motixafortide Plus G-CSF To Mobilize Hematopoietic Stem Cells in Multiple Myeloma
September 11th 2023The FDA has approved motixafortide in combination with filgrastim to mobilize hematopoietic stem cells in multiple myeloma transplantation, based on findings from the phase 3 GENESIS trial.
Mezigdomide Plus Dexamethasone Generates Encouraging Responses in R/R Myeloma
September 4th 2023Patients with heavily pretreated relapsed/refractory multiple myeloma, including those with lenalidomide and pomalidomide-refractory disease, showed encouraging responses with mezigdomide plus dexamethasone.
FDA Approves Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma
March 29th 2021The FDA has approved idecabtagene vicleucel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma after 4 or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.